simply becomes the safety threshold in the observational monitoring activity. If stated relative to no treatment, one must then determine the amount by which the comparator increases the risk of the outcome relative to no treatment in order to determine the maximum tolerable RR or RD comparing the new drug to the active comparator. This concept
is similar to selecting a NI margin in efficacy trials.